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Abstract: Atypical polypoid adenomyoma (APA) is a rare uterine
lesion constituted by atypical endometrioid glands, squamous morules,
and myofibromatous stroma. We aimed to assess the im-
munophenotype of the 3 components of APA, with regard to its
pathogenesis and its differential diagnosis. A systematic review was
performed by searching electronic databases from their inception to
January 2019 for immunohistochemical studies of APA. Thirteen
studies with 145 APA cases were included. APA glands appeared
analogous to atypical endometrial hyperplasia (endometrioid cyto-
keratins pattern, Ki67≤50%, common PTEN loss, and occasional
mismatch repair deficiency); the prominent expression of hormone
receptors and nuclear β-catenin suggest that APA may be a precursor
of “copy number-low,” CTNNB1-mutant endometrial cancers. Mor-
ules appeared as a peculiar type of hyperdifferentiation (low KI67,
nuclear β-catenin+, CD10+, CDX2+, SATB2+, p63−, and p40−),
analogous to morular metaplasia in other lesions and distinguishable
immunohistochemically from both conventional squamous metaplasia
and solid cancer growth. Stroma immunphenotype (low Ki67, α-
smooth-muscle-actin+, h-caldesmon−, CD10−, or weak and patchy)
suggested a derivation from a metaplasia of normal endometrial
stroma. It was similar to that of nonatypical adenomyoma, and dif-
ferent from adenosarcoma (Ki67 increase and CD10+ in periglandular
stroma) and myoinvasive endometrioid carcinoma (h-caldesmon+ in
myometrium and periglandular fringe-like CD10 pattern).
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A typical polypoid adenomyoma (APA) is an uncommonuterine lesion characterized by a proliferation of atypical
endometrial glands, with squamous morular metaplasia and
a typical fibromyomatous stroma.1–5
Histologically, APA may be difficult to differentiate
from myoinvasive endometrioid adenocarcinoma;1 fur-
thermore, morular metaplasia may mimic a solid growth
pattern.6 Such differential diagnosis appears even more
important, as APA affects premenopausal and nulliparous
women in most cases.3–5
However, despite being regarded as a benign lesion,
APA shows significant rates of progression to endometrial
cancer, and of recurrence when conservatively treated; these
findings, together with the presence of cytologic atypia, sup-
port the precancerous nature of APA.7,8 The relation of APA
with atypical endometrial hyperplasia (AEH, the precursor of
endometrioid adenocarcinoma)9,10 is still undefined, as well as
the origin of the features that distinguish APA from AEH (ie,
delimited polypoid appearance, squamous morules, and my-
ofibromatous stroma).11 Furthermore, it is also unclear how
APA is related to the 4 molecular categories of endometrial
cancer identified by The Cancer Genome Atlas (TCGA), that
is, “hypermutated,” “ultramutated,” “copy number-low,” and
“copy number-high.”12
Although molecular studies of APA have been
exceptional,11,13,14 most of the scientific evidence with regard
to the pathogenesis of APA may be gathered from im-
munohistochemical studies.6,11,13–25 Immunohistochemistry
has also played a major role in improving the differential
diagnosis of APA.6,22,23
The objective of our study was to provide a complete
overview of the immunophenotype of the 3 components of
APA (glands, morules, and stroma), to explore old and new
insights on its pathogenesis and its differential diagnosis.
MATERIALS AND METHODS
Study Protocol
This study was conducted following a protocol de-
fined a priori. All review stages, including search strategy,
study selection, risk of bias assessment, data extraction,
and data analysis, were conducted independently by 2
authors (A.T., A.R.). In case of disagreement, consensus
was achieved by discussion among authors. The review
was reported according to the PRISMA26 statement.
Search Strategy
MEDLINE, Scopus, EMBASE, Web of Sciences,
OVID, Google Scholar, and Cochrane Library were
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searched from the inception of each database to January
2019. The following combination of text words was used:
(atypical polypoid) AND (adenomyoma OR adenofi-
broma OR adenomyofibroma). References from relevant
articles were checked to identify further studies.
Study Selection
All studies reporting immunohistochemical features
of APA were included. Exclusion criteria were as follows:
same sample as a study already included, case reports, and
reviews. No language restrictions were applied,
Risk of Bias Assessment
The risk of bias was assessed in each study, in rela-
tion to 5 domains: (1) Selection (were APA specimens
selected consecutively? Were period of enrollment and
selection criteria reported?); (2) Diagnosis (were histologic
slides reviewed to confirm APA diagnosis? Were histologic
features of APA presented?); (3) Methodology (were
methods for immunohistochemistry clearly described?); (4)
Loss (were all included specimens evaluated im-
munohistochemically?); and (5) Results (were im-
munohistochemical results clearly and fully presented?).
For each domain, the risk of bias was categorized as
“low,” “high,” or “unclear,” depending on whether data
were “reported and adequate,” “reported, but not ad-
equate,” “not reported,” respectively.
Data Extraction
Data were extracted from each study without mod-
ifications. For each study, the main data extracted were
sample size, immunohistochemical markers assessed, in-
tensity of distribution of the expression of each marker,
and correlation with genetic findings (when possible).
Secondary data extracted were country, study design, pe-
riod of enrollment, location of APA around the uterus,
characteristics of the patients, and clinical behavior of
APA (ie, rates of recurrence and progression).
RESULTS
Selection and Characteristics of the Studies
Thirteen studies with a total of 145 APA specimens
were included.6,11,13,14,16,18,20–25,27 The fully reproducible
process of study selection on the electronic database
“MEDLINE” is presented in Figure 1. Sampling methods
for histologic examination varied among studies, including
hysterectomy, polypectomy, curettage, transcervical
resection, and hysteroscopic biopsy. Three studies
focused in particular on APA morules, comparing them
to conventional squamous metaplasia and/or to mo-
rular metaplasia in other lesions.6,20,21 Four studies
also assessed myoinvasive endometrioid adenocarcinoma
specimens, to identify diagnostic markers that may allow a
differential diagnosis with APA.18,22,23,27 In 1 study, APA
was compared with adenosarcoma and endometrial
polyp.25 Characteristics of the included studies are
shown in Table 1.
TABLE 1. Characteristics of the Included Studies
References Country Period of Enrollment Sample Size Sample Type
Fukunaga et al16 Japan 1991-1994 6 Hysterectomy, curettage, polypectomy
Soslow et al18 United States Unclear 23 Cutrettage, biopsy, hysterectomy,
polypectomy
Ota et al13 Spain Unclear 6 Hysterectomy, polypectomy
Chiarelli et al20 Italy, Spain Unclear 4 Curettage, aspiration, hysterectomy
Houghton et al21 United Kingdom Unclear 3 Unclear
Ohishi et al22 Japan Unclear 7 Curettage, hysterectomy
Horita et al23 Japan 2005-2010 6 Curettage, hysterectomy, transcervical
resection
Terada24 Japan Unclear 5 Hysterectomy, polypectomy
Aggarwal et al25 United States Unclear 14 Biopsy, curettage
Takahashi et al11 Japan 1990-2012 7 Curettage, hysterectomy
Němejcová et al14 Czech Republic; United
Kingdom
Unclear 21 Hysterectomy, curettage, polypectomy
McCluggage and Van de Vijver6 United Kingdom; Belgium Unclear 7 Unclear
Lu et al27 China 2003-2017 36 Polypectomy, hysterectomy
FIGURE 1. Flow diagram of study selection (PRISMA tem-
plate).
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Risk of Bias Assessment
The risk of bias in the “selection” domain was low in
6 studies (they clearly stated that specimens were consec-
utive, or reported at least the period of enrollment and
inclusion criteria) and unclear in 7 studies.6,13,14,20,22,24,25
For the “diagnosis” domain, the risk of bias was low
in 9 studies (histologic slides reviewed, morphologic fea-
tures of APA well presented) and unclear in 4.20,21,24,25
For the “methodology” domain, the risk of bias was
low in all studies (methods for immunohistochemistry
clearly described).
For the “loss” domain, 12 studies were considered at
low risk (no exclusion of specimens from im-
munohistochemistry, or exclusion explained by tissue un-
availability), and 1 at unclear risk.20
For the “results” domain, 9 studies were at low risk,
2 at unclear risk (APA and other lesions lumped
together),20,21 and 1 at high risk (discrepancy between text
and figures) (Fig. 2).25
Immunohistochemistry
Glands
The glandular component of APA showed positivity
for cytokeratins CAM5.2,18 AE1/AE3, 8, 18, 7, and 19;
the expression of cytokeratins 34βE12, 5/6, and 13 was
variable; cytokeratins 14 and 20 were negative.24
The expression of the proliferation marker Ki67 was
highly variable, with a labeling index (L.I.) ranging from 0
to almost 50%.11,23–25,27
Estrogen and progesterone receptors were expressed
strongly and diffusely in 95% to 100% of cases.18,24,27
Among the molecules involved in endometrial car-
cinogenesis, PTEN was frequently lost (about 1/3 of cases)
or deficient, as confirmed by the finding of PTEN muta-
tion on molecular analysis.14 mTOR was expressed in 90%
of cases, with variable intensity.14 Nuclear expression of β-
catenin was observed in 50% to 80% of cases, with high
variability in the intensity.11,13,14 Among mismatch repair
proteins, MLH1 was found to be deficient in only 2 cases
(correspondent to MLH1 methylation status), whereas
MSH2, MSH6, and PMS2 were always proficient.13,14
Expression pattern of p53 was normal, as well as TP53
status (wild type).14,23,24
Among tumor markers, CA125 was always strongly
expressed; the expression of CA19.9 was variable, whereas
CEA was negative.16,24 The expression of p21, cyclin D1
and cyclin E was highly variable.11,27
Expression profile of mucins showed positivity for
MUC1 and MUC6 and negativity for MUC2 and
MUC5AC.24
Immunohistochemical findings for the glandular
component of APA are shown in detail in Table 2.
Morules
Expression profile of cytokeratins showed positivity
for cytokeratins 903,22 CAM5.218 8, 18, and 19; weak
positivity for cytokeratins 34βE12, 5-6, and 13; and neg-
ativity for cytokeratins 7 and 20.20
The expression of estrogen and progesterone re-
ceptors was absent, or weaker compared with the glan-
dular component 18,20,21; also, cellular proliferation,
assessed as Ki67 L.I., was low (0% to 5%).11,27
The expression of the squamous markers p40 and
p63 was negative, whereas unexpected expression of
CDX2 and SATB2 was observed.6,21,27 Unlike the glan-
dular component, and in contrast with conventi-
onal squamous metaplasia, morules were positive for
CD10.11,20–23,25,27
Nuclear expression of β-catenin was both stronger
and more diffuse than in glands.11,13,14,20,21,27
Immunohistochemical findings for the morular
component of APA are shown in detail in Table 3.
Stroma
The myofibromatous stroma of APA was always
positive for α-smooth-muscle-actin (strong and diffuse
positivity in 70% to 100% of cases),11,16–18,22–25,27, whereas
the expression of desmin, vimentin, CD10, and CD34 was
variable;11,16,18,22–25 S100 was negative.24
h-caldesmon, a smooth muscle marker, was always
completely negative in APA stroma (positive only in ves-
sels).23,27 In 1 study, the authors stated in the text that
smooth muscle markers (also including h-caldesmon) were
positive in the stroma of APA, whereas the figure clearly
showed that h-caldesmon was negative.25
FIGURE 2. Risk of bias summary: review authors’ judgments
about each risk of bias item for each included study. Question
mark indicates unclear risk of bias; minus sign, high risk of bias;
NA, not applicable; plus sign, low risk of bias.
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Ki67 L.I. was sensibly lower than in glands (0% to
10%).11,23–25 Estrogen receptor was always expressed, with
variable extent and intensity; the expression of progester-
one receptor varied.18,24
Immunohistochemical findings for the stromal
component of APA are shown in detail in Table 4.
Immunohistochemical expression of the markers
studied in the differential diagnosis between APA and
myoinvasive endometrioid adenocarcinoma is detailed in
Table 5.
TABLE 2. Immunohistochemical Findings in APA Glands
Ki67
Horita et al23 Variable (L.I. 2.9%-44.7%)
Tearada et al24 Variable (L.I. 3%-12%)
Aggarwal et al25 More intense than in stroma
Takahashi et al11 Variable (L.I. 0.8%-30%)
Lu et al27 Variable (L.I. 20.86± 16.51%)
Cytokeratins
Soslow et al18 CAM5.2 positive
Terada24 CKAE1/AE3, CAM5.2, CK8, and CK18 strongly
positive; CK7 and CK19 positive (variable intensity);
CK34βE12, CK5/6, and CK13 variable; CK14 and
CK20 negative
β-catenin
Ota et al13 Nuclear in 5/6 cases
Takahashi et al11 Variably nuclear (L.I. 5%-55.3%)
Nemejcova et al14 Nuclear in 12/21 cases
Lu et al27 Nuclear (focal and weak)
p53
Horita et al23 Always normal
Terada24 Always normal
Nemejcova et al14 Always normal
Estrogen receptor
Soslow et al18 Always prominent
Terada24 Always diffusely positive
Lu et al27 Strongly and diffusely positive
Progesterone receptor
Soslow et al18 Always positive (prominent in 22/23 cases)
Terada24 Always diffusely positive
Lu et al27 Strongly and diffusely positive
Mismatch repair proteins
Ota et al13 MLH1 focally negative in 2/6 cases; MSH2 always
normal
Nemejcova et al14 MLH1, MSH2, MSH6, and PMS2 always normal
Mucins
Terada24 MUC1 positive (weak to strong intensity); MUC6
positive (weak intensity); MUC2 and MUC5AC
negative
CEA
Fukunaga et al16 Negative
Terada24 Negative
CA125
Terada24 Always positive
CA19.9
Terada24 Variable
p21
Takahashi et al11 Variable (L.I. 0.7%-18.8%)
Cyclin D1
Takahashi et al11 Variably positive (L.I. 17.2%-81.8%)
Lu et al27 Positive
Cyclin E
Takahashi et al11 Variable (null to diffuse)
PTEN
Nemejcova et al14 Null in 6/21 of cases, positive (variable L.I.) in 15/21
GLUT-1
Nemejcova et al14 Always positive (variable intensity)
mTOR
Nemejcova et al14 Positive in 17/19 cases
HNF1β
Nemejcova et al14 Positive in 16/21 cases
EMA
Terada24 Negative
SOX9
Lu et al27 Positive
APA indicates atypical polypoid adenomyoma; L.I., labeling index.
TABLE 3. Immunohistochemical Findings in APA Morules
CD10
Chiarelli et al20 Positive
Houghton et al21 Positive in 16/17 cases
Ohishi et al22 Diffuse and strong
Horita et al23 Positive
Aggarwal et al25 Positive
Takahashi et al11 Positive
Lu et al27 Positive
β-catenin (nuclear)
Ota et al13 Positive and stronger than in glands in 4/5
cases
Chiarelli et al20 Positive
Houghton et al21 Positive in 16/18 cases
Takahashi et al11 Positive and stronger than in glands
Nemejcova et al14 Positive and stronger than in glands in 15/
19 cases
Lu et al27 Positive and stronger than in glands
Estrogen receptor
Soslow et al18 Variable
Chiarelli et al20 Negative
Houghton et al21 Negative in 12/18 cases
Lu et al27 Almost null
Progesterone receptor
Soslow et al18 Variable
Chiarelli et al20 Negative
Lu et al27 Almost null
Ki67
Takahashi et al11 Low (L.I. 0.8%-5%)
Lu et al27 Low (L.I. 1.52± 0.83%)
CDX2
Houghton et al21 Diffuse in 14/17 cases
Lu et al27 Diffuse and strong
Cytokeratins (CK)
Soslow et al18 CAM5.2 positive
Chiarelli et al20 CK8, CK18, and CK19 positive; CK5-6,
CK13, and CK34βE12 weak; CK7 and
CK20 negative
Ohishi et al22 CK903 positive
p63
Houghton et al21 Negative in 16/17 cases
p40
Lu et al27 Null to weak and focal
p21
Takahashi et al11 From focal to diffuse
Cyclin D1
Takahashi et al11 Always positive (L.I. 35%-76%)
Lu et al27 Positive (weaker than in glands)
Cyclin E
Takahashi et al11 Null to diffuse in all components
GLUT-1
Nemejcova et al14 Always positive (variable intensity)
SATB2
McCluggage and Van de
Vijver6
Diffuse in 38/43 cases
LP34
Houghton et al21 Diffuse in 17/18 cases
SOX9
Lu et al27 Positive (weaker than in glands)
APA indicates atypical polypoid adenomyoma; L.I., labeling index.
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DISCUSSION
APA Glands, AEH, and TCGA Groups
APA glands are indistinguishable from AEH,11 and
the cytokeratins’ expression pattern does not differ from
other endometrioid proliferations.15,18,24 The proliferation
index, evaluated as Ki67 L.I., can be moderately increased
in APA, with a significant overlap of values with endo-
metrioid carcinoma. However, whereas Ki67 L.I. seems to
never exceed 50% in APA, it could be even over 90% in
endometrioid carcinoma.23,27
These findings, together with the possibility of defi-
cient expression of PTEN, support the premalignant na-
ture of APA and its similarity to AEH.11,14,23,28–33 In fact,
it has been suggested that APA may be a localized form of
AEH11; furthermore, the use of IHC for distinguishing
APA from AEH is discouraged by ESGO guidelines.34 In
this regard, it would be interesting to assess APA for other
molecules that are frequently altered in AEH, such as Bcl-
2, ARID1A, and PAX2.35–37
Remarkably, APA is reported to be associated with
mismatch repair deficiency in the 2014 WHO classification
of gynecologic tumors.9 On the basis of only 1 study,13
such a statement seems to suggest a particular association
of APA with microsatellite instable endometrial cancers of
the TCGA “hypermutated” group.12,38 However, ac-
cording to our review, mismatch repair proteins are only
rarely deficient in APA, similarly to AEH.13,14,39
Estrogen and progesterone receptors were always
found to be strongly and diffusely expressed in APA
glands, whereas AEH may sometimes show low or absent
expression.40 Consistently, progestins have been used as a
conservative treatment for APA.41–43 Interestingly, our
TABLE 4. Immunohistochemical Findings in APA Stroma
αSMA
Fukunaga et al16 Always strong and diffuse
Soslow et al18 Always positive (strong and diffuse in
17/23 cases)
Ohishi et al22 Always diffuse and strong
Horita et al23 Always positive
Terada24 Always diffusely positive
Aggarwal et al25 Positive
Takahashi et al11 Strong and diffuse
Lu et al27 Strongly positive
CD10
Ohishi et al22 Negative or focal and weak
Horita et al23 Negative or partially positive
Terada24 Always positive
Takahashi et al11 Negative or focal and weak
Lu et al27 Focally positive
Desmin
Fukunaga et al16 Positive in 30%-85% cells
Soslow et al18 Variable (negative to focal and
intense)
Ohishi et al22 Negative or weak and focal
Terada24 Variable
Aggarwal et al25 Positive
Ki67
Horita et al23 Variable (L.I. 0.3%-10.8%)
Terada24 Variable (L.I. 1%-8%)
Aggarwal et al25 Low (L.I. <5%)
Takahashi et al11 Low (L.I. 0.8%-2.8%)
H-caldesmon
Horita et al23 Negative (positive only in vessels)
Aggarwal et al25 Unclear (positive in text, negative in
figure)
Lu et al27 Negative
Vimentin
Fukunaga et al16 Always diffuse
Terada24 Positive in 4/5 cases
Estrogen receptor
Soslow et al18 Always positive
Terada24 Always diffusely positive
Progesterone receptor
Soslow et al18 Variable
Terada24 Always diffusely positive
S100
Terada24 Negative
HHF35
Fukunaga et al16 Diffuse and intense
CD34
Soslow et al18 Variable (negative/weak in 21/22
cases)
p21
Takahashi et al11 Variable (L.I. 0.6%-51.4%)
Cyclin D1
Takahashi et al11 Variable (L.I. 1.7%-38.1%)
Cyclin E
Takahashi et al11 Null to diffuse
EMA
Terada24 Negative
SATB2
McCluggage and Van de
Vijver6
Diffusely positive
APA indicates atypical polypoid adenomyoma; L.I., labeling index.
TABLE 5. Immunohistochemical Comparison Between APA
and Myoinvasive Endometrioid Adenocarcinoma
APA
Myoinvasive Endometrioid
Adenocarcinoma
Glands
Cytokeratin
CAM5.218
Always positive Always positive
Estrogen
receptor18
Always positive Positive in 90%
Progesterone
receptor18
Always positive Positive in 90%
p5323 Always normal (L.I.
2.1%-40.1%)
Always normal (L.I. 0.2%-
14.4%)
Ki6723 Variable (L.I. 2.9%-
44.7%)
Variable (L.I. 14.4%-92.3%)
Stroma
αSMA22,23,27 Always positive Always positive
Desmin18,22 Positive in 17/30 cases Positive in 26/29 cases
CD3418 Positive in 9/22 cases Positive in 4/8 cases
CD1022,23 Negative or weakly
positive
Fringe-like pattern (5%-100%
of glands)
h-
caldes-
mon23,27
Always negative Always positive
Estrogen
receptor18
Always positive
(variable intensity)
Variable
Progesterone
receptor18
Variable Variable
p5323 Always normal (L.I.
1.3%-32.9%)
Always normal (L.I. 0.1%-
5.8%)
Ki6723 L.I. 0.3%-10.8% L.I. 1.5%-7.2%
APA indicates atypical polypoid adenomyoma; L.I., labeling index.
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previous study showed that the addition of progestins did
not significantly improve the outcomes of APA treatment
if compared with hysteroscopic resection alone.5 By con-
trast, the addition of progestins is required for AEH.44,45
Reasons for such a difference are unclear, although it
might be due to the delimited polypoid morphology of
APA, which might facilitate a complete excision.
Strong hormonal receptors’ expression was also ob-
served in cancers developed from APA, which usually are
low-grade endometrioid carcinomas.46 These findings
suggest that most APAs may be precursors of endometrial
cancers of the “copy number-low” group identified by
TCGA.12 Such hypothesis may also be supported by the
characteristic nuclear expression pattern of β-catenin in
APA epithelial component (more prominent in morules).
In fact, Takahashi et al11 showed that nuclear β-catenin
reflected the presence of CTNNB1 mutations in APA, and
CTNNB1 mutations are particularly frequent in the “copy
number-low” group.12 Consistently, in our previous study,
we showed that nuclear expression of β-catenin was an
accurate immunohistochemical surrogate of CTNNB1
exon 3 mutations in endometrial cancer.47
Given these observations, the main molecular di-
vergence between APA and AEH in endometrial carci-
nogenesis may not lie in mismatch repair deficiency, but in
CTNNB1 mutation, which might also be responsible for
APA peculiar histology (see below). Indeed, nuclear ex-
pression of β-catenin is much less common in AEH.39
Interestingly, CTNNB1 mutations have a prognostic
significance in the “copy number-low” cancers, identifying
cases at worse prognosis.48 Consequently, CTNNB1 mu-
tation has been proposed as a marker to define a separate
subgroup within the copy number-low group.49 It might
reasonably be hypothesized that most APAs represent
precursors of cancers of this specific subgroup.
As in AEH, the main available marker of the “copy
number-high” group, namely overexpression of p53,38 was
never observed in APA. Finally, the relation of APA with
the “ultramutated” group is still unclear.
APA Morules, Squamous Differentiation, and
Solid Tumor Growth
A characteristic feature of APA epithelial compo-
nent is the presence of squamous morules, which can be
observed less commonly in AEH and in endometrioid
carcinoma. Despite being referred to as “squamous mor-
ular metaplasia,” their immunophenotype is completely
different from that of conventional squamous metaplasia.
In fact, they are usually negative for the squamous
markers p40 and p63, and diffusely positive for CD10 and
the heterotopic markers CDX2 and SATB2.6,20,21,27 In
this regard, it has been proposed that morules are not truly
squamous and that morular pattern is a separate differ-
entiation, which should be referred to as “morular meta-
plasia.”6
On differential diagnosis, such peculiar immuno-
phenotype may also allow differentiating morular meta-
plasia from a cancer with solid growth.6 In addition, the
insignificant Ki67 L.I. also would be incompatible with a
solid carcinoma. In fact, in APA, as in AEH, morules
seems to be an “inert” component.11,27,50 A prodiffer-
entiative mechanism, which involves p21, cyclin D1, and
β-catenin (all overexpressed in APA morules), has been
suggested as the origin of morular metaplasia.11 In par-
ticular, nuclear expression of β-catenin is almost always
present in APA morules, appearing stronger and more
diffuse than in glands.11,13,14,20,21,27
APA Stroma, Mullerian Tumors,
and Myoinvasive Cancer
The origin of the peculiar stroma of APA is unclear. A
metaplastic change of the normal endometrial stroma to a
myofibromatous stroma has been proposed as the main
mechanism.4,11,22 The combination of strong and diffuse
positivity for αSMA and complete negativity for h-caldes-
mon appears as a hallmark of the stroma of APA and of a
subset of nonatypical adenomyomas.23,27,51 Weak and pat-
chy CD10 expression may still be observed, indicating the
presence of endometrial stromal cells admixed with the fi-
bromyomatous component.11,22,23 Hormonal action might
be the driver mechanism for the metaplastic stromal change.
Such hypothesis is supported by the evidence that the normal
endometrial stroma expresses αSMA in the secretory
phase.11 Anyway, the stroma of APA does not seem to share
the immunohistochemical alterations of the glandular com-
ponent, and also the Ki67 L.I. is lower.11,24,25 This finding
could differentiate APA from other more aggressive mul-
lerian tumors in which stroma is an active component of the
neoplasm. In particular, adenosarcoma shows significant
increase of the Ki67 L.I. in the periglandular stroma, which
is positive for CD10.25
CD10 was also proposed as a diagnostic marker to
differentiate APA from myoinvasive endometrial cancer.
In fact, the latter one may show a CD10-positive fringe-
like area surrounding neoplastic myoinvasive glands,
which is absent in APA. However, this pattern was in-
constant and might be observed in as little as 5% of
glands.22,23 In contrast, h-caldesmon appeared as a highly
valuable diagnostic marker, as it was always diffusely
positive in the infiltrated myometrium.23,27
Strengths and Limitations
To the best of our knowledge, this is the first sys-
tematic review that assessed immunohistochemical fea-
tures of APA. We evaluated the immunohistochemical
markers separately for the different components of APA,
discussing their pathogenic significance and their relation
with AEH and with the 4 TCGA molecular groups of
endometrial cancer. Moreover, we dealt with the possible
application of immunohistochemistry in the differential
diagnosis of APA.
The main limitation to our results lies in the rarity of
APA, which results in a relatively small sample size. Moreover,
the low number of molecular analyses and the lack of corre-
lation with the prognosis might limit our results. Furthermore,
some included studies showed limits in the presentation of
data, as discussed in the “risk of bias assessment” results.
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CONCLUSIONS
Immunohistochemically, APA appears as a variant of
AEH with constant strong expression of hormone receptors
and nuclear expression of β-catenin; this suggests that most
APAs might be precursors of a subset of “copy number-low”
endometrial cancer, characterized by CTNNB1 mutation
and a different prognosis.
APA morules appear as an “inert” component,
which may derive from a prodifferentiative mechanism.
On the basis of their peculiar immunophenotype, they can
be differentiated from both a conventional squamous
metaplasia and a solid tumor growth. In contrast, APA
morules do not differ from morular metaplasia in other
endometrioid proliferations.
The myofibromatous stroma of APA is similar to
that of nonatypical adenomyoma; it may derive from en-
dometrial stroma through a metaplastic, hormone-driven
process. The low Ki67 L.I. may exclude a more aggressive
mullerian tumor such as adenosarcoma. Negativity for
h-caldesmon might be highly reliable for excluding a
myoinvasive cancer; moreover, the latter one may show an
inconstant fringe-like CD10 pattern, which is absent
in APA.
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